Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucos...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285615612659 |
id |
doaj-e294c48ba8874abcaef7051c19b53774 |
---|---|
record_format |
Article |
spelling |
doaj-e294c48ba8874abcaef7051c19b537742020-11-25T03:34:54ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642016-01-01910.1177/1756285615612659Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosisUwe K. ZettlPaulus RommerPetra HippRobert PatejdlSpasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about,1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than,1000 patient-years are presented.https://doi.org/10.1177/1756285615612659 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Uwe K. Zettl Paulus Rommer Petra Hipp Robert Patejdl |
spellingShingle |
Uwe K. Zettl Paulus Rommer Petra Hipp Robert Patejdl Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis Therapeutic Advances in Neurological Disorders |
author_facet |
Uwe K. Zettl Paulus Rommer Petra Hipp Robert Patejdl |
author_sort |
Uwe K. Zettl |
title |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
title_short |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
title_full |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
title_fullStr |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
title_full_unstemmed |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
title_sort |
evidence for the efficacy and effectiveness of thc-cbd oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Neurological Disorders |
issn |
1756-2856 1756-2864 |
publishDate |
2016-01-01 |
description |
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about,1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than,1000 patient-years are presented. |
url |
https://doi.org/10.1177/1756285615612659 |
work_keys_str_mv |
AT uwekzettl evidencefortheefficacyandeffectivenessofthccbdoromucosalsprayinsymptommanagementofpatientswithspasticityduetomultiplesclerosis AT paulusrommer evidencefortheefficacyandeffectivenessofthccbdoromucosalsprayinsymptommanagementofpatientswithspasticityduetomultiplesclerosis AT petrahipp evidencefortheefficacyandeffectivenessofthccbdoromucosalsprayinsymptommanagementofpatientswithspasticityduetomultiplesclerosis AT robertpatejdl evidencefortheefficacyandeffectivenessofthccbdoromucosalsprayinsymptommanagementofpatientswithspasticityduetomultiplesclerosis |
_version_ |
1724556726827483136 |